Brenetafusp
Tebentafusp's successor: a soluble T-cell receptor that recognises a fragment of PRAME, a protein present in most melanomas and many other cancers, and drags T cells onto the tumour.
Phase 1/2 in heavily pretreated cutaneous melanoma: median OS 14.3 months on monotherapy (ASCO 2026 update). PRISM-MEL-301 phase 3 with nivolumab in first-line HLA-A*02:01-positive melanoma is enrolling; further trials in ovarian, lung, and endometrial cancer. Requires HLA-A*02:01 (roughly half of European-ancestry patients).
1.The TCR arm binds PRAME peptide displayed on HLA-A*02:01 on the tumour cell
- Route
- Intravenous
- Schedule
- Weekly with step-up dosing to 160 µg
- Monitoring
- Cytokine release syndrome during the first doses; rash
Source: clinicaltrials.gov/study/NCT06112314. Doses are for orientation; the current label governs.
Compare all products across the US, EU, UK, Japan, China and Australia →
- 2024DesignationUS
Phase 3 PRISM-MEL-301 initiated after FDA alignment on design
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Brenetafusp" OR ABSTRACT:"Brenetafusp" OR TITLE:"IMC-F106C" OR ABSTRACT:"IMC-F106C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Brenetafusp, not a curated reading list.
Pages like this
not linked directly; found by shared links- TrialIMCgp100-202
Shares Immunocore, Tebentafusp, CD3, T-cell engagers (bispecific).
- InstitutionOxford Cancer – Oxford University Hospitals and University of Oxford
Shares Immunocore, Tebentafusp, T-cell engagers (bispecific), Ovarian cancer.
- Targetgp100 (PMEL)
Shares Tebentafusp, Uveal melanoma, T-cell engagers (bispecific), Melanoma.
- CompanyXencor
Shares CD3, T-cell engagers (bispecific), Ovarian cancer.
- IdeaAntibodies that see mutant KRAS and p53 fragments displayed on the cell surface
Shares Immunocore, Tebentafusp, T-cell engagers (bispecific).
- CollectionMelanoma Research Alliance (MRA)
Shares Uveal melanoma, Melanoma.
- TechnologyPercutaneous hepatic perfusion (chemosaturation)
Shares Tebentafusp, Uveal melanoma.
- TrialTOWER
Shares CD3, T-cell engagers (bispecific).